Archives
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Very recently Niessen et al have described the resensitizing
2023-09-14

Very recently, Niessen et al. have described the resensitizing effect of MB327 on nAChR performing solid-supported membrane (SSM)-based electrophysiological experiments (Niessen et al., 2016) using plasma membrane preparations obtained from Torpedo californica. These findings validated and underline
-
Inactivation of the proton pump
2023-09-14

Inactivation of the proton pump comes with luminal alkalinization of the targeted vesicles such as lysosomes (Fig. 2b). Lysosome pH can also be raised stoichiometrically by addition of a membrane-permeable weak Phos-tag Biotin such as methylamine or chloroquine which accumulates in its protonated,
-
Another contributor for the G M arrest in A
2023-09-14

Another contributor for the G2/M arrest in A549 and H1299 cells might be p21WAF1/CIP1 which was up-regulated upon ovatodiolide treatment. p21WAF1/CIP1 is a common CDKs inhibitor which blocks AGK 2 G2/M phase progression in various types of cancer cells (Kim et al., 2015, Liberio et al., 2015). It h
-
Similarly compound was prepared from aldehyde d by following
2023-09-13

Similarly, 1145 13 was prepared from aldehyde 8d by following similar procedures (Scheme 3). Condensation of 13 with 7b or 7e provided the corresponding amides 9j or 9k, which then went through O-debenzylation by BCl3 to deliver the final compounds 10j and 10k in 37% and 32% overall yields, respect
-
br Material and methods br Results
2023-09-13

Material and methods Results Discussion Neurotransmitters pathways within vertebrates, including fish, are well conserved (Kreke and Dietrich, 2008, Valenti et al., 2012). Therefore psycopharmaceuticals that are design to act on these pathways in mammals, will possibly interact with the sam
-
Mechanistically NAergic signaling in the VTA modulates neuro
2023-09-13

Mechanistically, NAergic signaling in the VTA modulates neuronal activity presumably via α1-AR. The majority of α1-ARs are found in the VTA are located presynaptically on unmyelinated MRS1523 and axon terminals of glutamatergic and GABAergic neurons. However, α1-ARs are also found on neuronal dendr
-
Iberiotoxin br Introduction Cell motility is fundamentally i
2023-09-13

Introduction Cell motility is fundamentally important in morphogenesis, wound healing, and the immune response. One of the best-studied basic types of cell movement is lamellipodial motility [1, 2], characterized by a thin (∼0.1–0.2 μm), broad (∼10–40 μm) motile appendage containing a dynamic Ibe
-
br Acknowledgements br Introduction Autoantibodies directed
2023-09-13

Acknowledgements Introduction Autoantibodies directed at neurotransmitter receptors and ion channels are pathogenic and/or biomarkers in several autoimmune neurological diseases [1]. For example, autoantibodies directed against voltage-gated potassium channels, the P/Q-type (α1A) voltage-gated
-
br Extracellular domain architecture The extracellular regio
2023-09-13

Extracellular domain architecture The extracellular region of GABAB receptor exists in a heterodimeric configuration regardless of interactions within the rest of the protein (Geng et al., 2012, Liu et al., 2004, Nomura et al., 2008). The extracellular domains of the GABAB1 and GABAB2 subunits ar
-
To the best of our
2023-09-13

To the best of our knowledge, only 3 cases of an E196K mutation have been described since it was first identified in 2000 [15], [16], [17], although 5 cases, accounting for 1.1% of all genetic TSE cases, were reported with no precise data on the clinical phenotypes in the EUROCJD collaborative surve
-
It has been reported that trehalose shows beneficial effects
2023-09-12

It has been reported that trehalose shows beneficial effects in a mouse model of several neurodegenerative diseases [21], [22], [23]. There are also reports showing that trehalose can improve the impaired cognitive and learning ability and reduced Aβ deposit in hippocampus of APP/PS1 transgenic mice
-
Previous studies have demonstrated that synaptic AMPARs
2023-09-12

Previous studies have demonstrated that synaptic AMPARs can differ greatly in their mobility; some rapidly and constitutively topoisomerase inhibitors in and out of the synaptic membrane, while others remain somewhat stable in the synaptic membrane (Luscher et al., 1999, Luthi et al., 1999). We fin
-
Although only Leu CysAP IRAP Herbest et
2023-09-12

Although only Leu/CysAP (IRAP) (Herbest et al., 1997, Keller, 2004) and DPPIV (Alponti and Silveira, 2010, Kirino et al., 2009) had been identified and studied in adipocytes, our kinetic analysis suggested the highest physiological significance for AspAP (highest affinity) and APM and PSA (highest e
-
It is noteworthy to mention
2023-09-12

It is noteworthy to mention the limitations of this study like tPA plus LB1 treatment beyond 4 h after stroke was not investigated. Especially 6 or 8 h after stroke could be studied in future projects for translational purposes. Second drawback might be that we performed the experiments in different
-
We next developed a system for staging
2023-09-12

We next developed a system for staging severity. Our guiding principles were the following. Two types of information about the research participant are staged independently from each other: (1) grading disease severity using biomarkers and (2) grading the severity of cognitive impairment. Measures u
15769 records 272/1052 page Previous Next First page 上5页 271272273274275 下5页 Last page